The July 2026 FDA calendar includes crucial PDUFA dates that might influence oncology and chronic disease management. Three major drugs are nearing approval, poised to affect thousands of patients and potentially shift company stock performance. Investors should track these developments as they unfold this month.

The full July 2026 PDUFA calendar

Relacorilant: A Promising Candidate for Platinum-Resistant Ovarian Cancer

Relacorilant from Corcept Therapeutics (ticker: CORT) is up for a PDUFA date on July 11, 2026. It shows promise for treating platinum-resistant ovarian cancer. The ROSELLA trial, with 381 patients across 14 countries, showed a 30% reduction in disease progression risk and improved median progression-free survival (PFS) by 6.54 months compared to the control, nab-paclitaxel. With a 70% approval probability, backed by Orphan Drug and Fast Track designations, Relacorilant stands strong. However, the open-label trial design may introduce bias in patient-reported outcomes, and a recent FDA Complete Response Letter raises concerns about liver injury. The drug's strong efficacy and regulatory support make it a significant contender in July's PDUFA calendar.

FUROSCIX ReadyFlow™ Autoinjector: A New Era in Diuretic Delivery

MannKind Corporation (ticker: MNKD) is looking at a PDUFA decision on July 26, 2026, for the FUROSCIX ReadyFlow™ Autoinjector. This device targets edema in adults with chronic heart failure and chronic kidney disease. The approval probability is a promising 73%, thanks to a pivotal trial showing 107.3% bioavailability compared to intravenous furosemide. This application could revolutionize drug delivery, cutting administration time from five hours to under ten seconds, aligning with FDA preferences for patient-friendly solutions. However, the trial's small sample of 21 healthy volunteers raises concerns about broad safety and efficacy. MannKind's past regulatory challenges, notably with Afrezza, suggest caution. Investors should closely watch the July 26 decision, as it could greatly affect the company's market position.

Gedatolisib: Targeting Advanced Breast Cancer

Celcuity (ticker: CELC) is anticipating a decision on gedatolisib for HR+/HER2-/PIK3CA wild-type advanced breast cancer on July 17, 2026. Although the approval probability isn't specified, early trials look promising, with a 17.6% stock value increase leading up to this date. Gedatolisib targets the PIK3CA pathway, a key player in many breast cancers, potentially offering a new treatment for patients with few options. Breast cancer is a competitive field, and gedatolisib's approval could boost Celcuity's market presence. The lack of specific probability metrics makes the investment risk higher as the PDUFA date approaches.

MR-100A-01: Investigational Patch for Contraception

Viatris (ticker: VTRS) is targeting a PDUFA date of July 30, 2026, for MR-100A-01, a low-dose estrogen contraceptive patch. The high approval probability, highlighted by its focus on women of childbearing potential, could introduce a new delivery mechanism in the contraceptive market. With growing demand for innovative contraceptives, MR-100A-01 could position Viatris advantageously against existing options. However, how it fits into the current landscape will be crucial for its market uptake. Investors should keep watch as the approval date nears, given the potential impact on sales and valuation.

Market Implications of July 2026 Approvals

The FDA approvals in July 2026 could significantly affect their respective markets, notably in oncology and chronic disease management. Relacorilant's expected approval could change treatment approaches for platinum-resistant ovarian cancer, considering its solid clinical data and regulatory designations. MannKind's FUROSCIX ReadyFlow™ Autoinjector could enhance outpatient management of chronic heart failure and kidney disease, tapping into a growing market for patient-friendly drug delivery systems. If approved, gedatolisib would give Celcuity a competitive edge in the breast cancer sector, though the absence of specific approval probability adds uncertainty. Viatris' contraceptive patch offers an innovative approach, potentially meeting unmet market needs. These approvals could profoundly influence stock performances and market dynamics.

Navigating Risks and Opportunities

Analyzing the FDA calendar for July 2026 reveals both risks and opportunities tied to these upcoming approvals. Each drug faces unique challenges, from trial design issues to regulatory hurdles. Relacorilant's open-label trial design could introduce biases affecting approval outcomes. MannKind's past regulatory challenges might dampen investor sentiment, despite strong bioavailability data. Gedatolisib, while promising, lacks specific probability metrics, complicating investment decisions. Viatris' contraceptive patch, though innovative, will compete with established options. Investors must balance these risks against potential market opportunities, especially in oncology and chronic disease management.

The bottom line

The FDA's decisions on these drugs in July 2026 will be closely monitored by investors and healthcare professionals, given their potential to alter treatment landscapes.